Stroke after varicose vein foam injection sclerotherapy

Forlee, Martin; Grouden, M. C.; Moore, Dermot J.; Shanik, Gregor D.

doi:10.1016/j.jvs.2005.09.032

Cited by 196 publications

(146 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Another case reported a patient who developed right upper extremity weakness, frontal headache, and sweating after injection with 20 ml of polidocanol foam (0.5%). 21 The patient's weakness improved after 10 minutes and completely resolved within 2 weeks. The patient was later found to have a PFO.…”

Section: Adverse Eventsmentioning

confidence: 91%

Effectiveness of foam sclerotherapy for the treatment of varicose veins

Nael

Rathbun

2009

Vasc Med

View full text Add to dashboard Cite

Varicose veins (VVs) are associated with lifestyle-limiting symptoms and complications. Patients who fail compression therapy are candidates for more invasive treatments. This study evaluates the efficacy and safety of endovenous foam sclerotherapy (EFS) for the treatment of VVs in a US academic center. We reviewed medical records of a consecutive cohort of patients who underwent EFS over a 2-year period. The primary outcome measure was obliteration of VVs. The secondary outcome measures were symptomatic improvement, ulcer healing, recurrence, and adverse events. A total of 166 patients (217 legs) underwent EFS for pain (81%), pruritis (41%), swelling (17%), ulcerations (17%), thrombophlebitis (14%), and varix rupture (3%). Complete (65%) or near-complete (34%) obliteration was achieved in 215 (99%) legs after one injection. Additional injections achieved complete obliteration in 39 of 53 legs. Ninety-three percent (27/29) of active ulcers healed or were decreasing in size. Five ulcers and 11 VVs recurred. Common adverse events included pain and hyperpigmentation. Thrombosis, hematoma, skin necrosis, and neurologic events were rare. In conclusion, EFS appears to be a safe and effective outpatient therapy for the treatment of symptomatic and complicated VVs.

show abstract

Section: Adverse Eventsmentioning

confidence: 91%

Effectiveness of foam sclerotherapy for the treatment of varicose veins

Nael

Rathbun

2009

Vasc Med

View full text Add to dashboard Cite

show abstract

“…At least 16 cases of stroke following sclerotherapy have been published with 4 of them following liquid sclerosants and 12 cases following foam sclerotherapy [35][36][37][38][39][40][41][42] . A majority of the reported patients recovered completely with no long-term sequelae.…”

Section: Cerebrovascular Aementioning

confidence: 99%

Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose Veins

Yiannakopoulou¹

2016

Pharmacology

View full text Add to dashboard Cite

Background: Sclerotherapy has been extensively used in the treatment of valvular insufficiency of superficial veins. Although sclerotherapy seems safe, reports of serious adverse events (AE) have been published. This paper aims to review AE of sclerosing agents. Methods: Electronical databases were searched for identifying articles on local, serious and long-term AE of sclerotherapy. Results: Hyperpigmentation and matting are the most often local AE of sclerotherapy. Other local AE include superficial thrombophlevitis, pyoderma gangrenosum, pain, ulcer formation, and hypertrichosis. Local AE can be serious, that is, it can include cutaneous necrosis, intra-arterial injection with subsequent acute ischemia that can lead to amputation, and necrotizing fasciitis. Most data on systemic AE of sclerotherapy are extracted from case series and case reports. Systemic AE include neurological complications, such as ischemic stroke, transient ischemic attack, visual disturbances and cardiac toxicity, that is, myocardial infarction, Takotsubo cardiomyopathy, chest tightness, pulmonary embolism, deep vein thrombosis, septicemia, anaphylaxis. It is difficult to estimate the frequency of serious systemic AE of sclerotherapy. Conclusion: Physicians practicing sclerotherapy should be aware of the possible local and systemic AE of sclerotherapy, inform patients accordingly and be prepared for the appropriate management of the rare but possibly lethal serious AE.

show abstract

“…[8] Venous embolization of the foam sclerosants have been well tolerated, but the arterial ones have caused devastating effects. [13] Although CA is considered to be safer than the other sclerosants, it has a theoretical risk of deep vein thrombosis. Therefore, the peripheral emboli still can rarely be encountered despite the faster polymerization time.…”

Section: Discussionmentioning

confidence: 99%

Ultrasound-guided perforator vein sealing with cyanoacrylate glue

Başbuğ¹

2016

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Stroke after varicose vein foam injection sclerotherapy

Cited by 196 publications

References 11 publications

Effectiveness of foam sclerotherapy for the treatment of varicose veins

Effectiveness of foam sclerotherapy for the treatment of varicose veins

Safety Concerns for Sclerotherapy of Telangiectases, Reticular and Varicose Veins

Ultrasound-guided perforator vein sealing with cyanoacrylate glue

Contact Info

Product

Resources

About